Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

By

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant

By

In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

Ixazomib, Lenalidomide, Dexamethasone Effective But Increases Toxicity in Multiple Myeloma

By

Three-drug regimen twice a week achieved good response and long-term outcomes in patients with newly diagnosed multiple myeloma; however, regimen has higher toxicity than once weekly dose.

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma

By

The 18-month progression-free survival rate was 71.6% among patients treated with daratumumab plus VMP compared with 50.2% among patients treated with VMP alone.

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years

By

A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma

By

Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

RVD-Lite Has Comparable Efficacy, Improved Toxicity in Transplant-Ineligible MM

By

In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

Plateau-Oriented Induction Approach Inadequate in Transplant-Ineligible Multiple Myeloma

By

In this phase 2 study, 38 patients with previously untreated multiple myeloma who were ineligible for autologous stem cell transplantation were treated with a bortezomib-containing induction regimen until plateau.

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

Firefighters in World Trade Center Attacks Have Increased Risk of Multiple Myeloma

By

A case series demonstrates the prevalence of MGUS, a precursor condition to multiple myeloma, and subsequent development of MM in white firefighters who responded after the 9/11 attacks in New York City.

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

Lenalidomide Alone or With Dexamethasone Effective in Relapsed Multiple Myeloma

A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT

By

A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Common Oncologic Emergencies That Occur With Multiple Myeloma

Common Oncologic Emergencies That Occur With Multiple Myeloma

By

What are the common oncologic emergencies seen in patients with MM?

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

Multiple Myeloma Survival Decreased With High ADAR1 RNA Expression

ADAR1 knockdown reduces regeneration of high-risk multiple myeloma in patient-derived xenografts

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

Carfilzomib Associated With Cardiovascular Adverse Events in Multiple Myeloma

By

For this meta-analysis and systematic review, investigators compiled phase 1 to 3 prospective clinical trials of carfilzomib therapy for patients with MM that had evaluable toxic effects data.

No Increased Risk for Melanoma in Patients With MM

No Increased Risk for Melanoma in Patients With MM

By

An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

FDA Grants Breakthrough Therapy Designation to bb2121 for Multiple Myeloma

By

Breakthrough Therapy Designation was granted for bb2121, a novel CAR T-cell therapy indicated for patients with multiple myeloma who have undergone previous treatments.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Flow Cytometry Assesses Minimal Residual Disease in Multiple Myeloma

Flow Cytometry Assesses Minimal Residual Disease in Multiple Myeloma

The use of flow cytometry has demonstrated usefulness in multiple myeloma recurrence assessment.

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

By

Researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone.

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

A Rare Case of Simultaneous Second Malignancies in Relapsed Multiple Myeloma

By

A first-reported case of simultaneous intracranial plasmacytoma and malignant pericardial effusion in a woman with relapsed multiple myeloma previously treated with chemotherapy and allogenic HSCT is described.

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

By

Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

By

The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

By

Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab

[Cancer Management and Research] The research examines the various combination strategies for the treatment of multiple myeloma, with a focus on the use of elotuzumab.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs